Sensible Diagnostics, Inc

Sensible was spun-out in early 2023 from Curative with the goal of bringing its 10 minute PCR platform (the Sensible Platform) to market. While at Curative, Sensible's team witnessed and participated in running over 2 million molecular point-of-care COVID-19 tests in the field. Building on this experience Sensible's team spent 2+ years developing and fine-tuning the Sensible platform, which is designed for speed and affordability without sacrificing accuracy or usability. Sensible's goal is to make PCR point-of-care testing for infectious disease the standard of care. By reducing testing times and costs and improving usability, Sensible's platform makes this standard of care viable in a market full of products that don't. Caution: This device is under development, It has not been approved for marketing in the US by the FDA.